Abstract | BACKGROUND: In this study, the authors identified seven-year survivors after completion of the French multicenter Phase II trial of fotemustine for the treatment of metastatic malignant melanoma. METHODS: One hundred sixty-nine patients with metastatic malignant melanoma were included in this Phase II study. One hundred fifty-three patient records were evaluable with an overall response rate of 24.2%. RESULTS: Five of these patients are alive and in complete remission. One patient had a complete response after fotemustine administration and then relapsed. One patient had a partial response. Three patients had stable disease. These five patients underwent surgery for relapse or residual disease and subsequently achieved durable complete remission. CONCLUSIONS: Long term survival may be the outcome after surgical resection of residual metastatic melanoma after chemotherapy.
|
Authors | T Petit, C Borel, O Rixe, M F Avril, A Monnier, B Giroux, M Weil, D Khayat |
Journal | Cancer
(Cancer)
Vol. 77
Issue 5
Pg. 900-2
(Mar 01 1996)
ISSN: 0008-543X [Print] United States |
PMID | 8608481
(Publication Type: Clinical Trial, Journal Article, Multicenter Study)
|
Chemical References |
- Antineoplastic Agents
- Nitrosourea Compounds
- Organophosphorus Compounds
- fotemustine
|
Topics |
- Antineoplastic Agents
(therapeutic use)
- Disease-Free Survival
- Follow-Up Studies
- Humans
- Lymph Nodes
(surgery)
- Lymphatic Metastasis
- Melanoma
(drug therapy, secondary)
- Nitrosourea Compounds
(therapeutic use)
- Organophosphorus Compounds
(therapeutic use)
- Remission Induction
- Splenic Neoplasms
(secondary, surgery)
|